Lymphoepithelial carcinoma of the lung
Prepared with OnCo (onco.cc/prep/lymphoepithelial-carcinoma-lung/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
8 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example EBV-encoded RNA in situ hybridisation, PD-L1, p40 positive, TTF-1 negative, Epigenetic regulator mutations), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (all stages), which of the standard options do you recommend and why?
- 6.Am I a candidate for Pembrolizumab, and what side effects should I expect?
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: EBV-encoded RNA in situ hybridisation, PD-L1 (overexpressed in about three quarters), p40 positive, TTF-1 negative, Epigenetic regulator mutations (research).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- All stages: Treated as squamous cell carcinoma of the lung; checkpoint inhibitors in advanced disease on the PD-L1 findings, without a dedicated trial. (Squamous cell carcinoma of the lung, Pembrolizumab)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.